Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents
David H. Canaday, Lenore L. Carias, Oladayo A. Oyebanji, Debbie Keresztesy, Dennis Wilk, Michael Payne, Htin Aung, Kerri St. Denis, Evan C. Lam, Christopher F. Rowley, Sarah D. Berry, Cheryl Cameron, Mark J. Cameron, Brigid Wilson, Alejandro B. Balazs, Stefan Gravenstein, Christopher L. King
Abstract
After BNT162b2 messenger RNA vaccination, antibody levels to spike, receptor-binding domain, and virus neutralization were examined in 149 nursing home residents and 110 healthcare worker controls. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-naive nursing home residents' median post-second vaccine dose antibody neutralization titers are one-quarter that of SARS-CoV-2-naive healthcare workers.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)VaccinationCoronavirusSevere acute respiratory syndrome coronavirus2019-20 coronavirus outbreakAntibodyTiterVirologyAntibody responseNursing homesImmunologyInternal medicineNursingOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyVaccine Coverage and Hesitancy